Trial Profile
A Double-Blind, Randomized, 2-Period Crossover, Placebo Controlled Study to Asses the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MK0822.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 23 Mar 2009 New trial record